Novo Nordisk A/S (NVO) News

Novo Nordisk A/S (NVO): $79.64

-0.94 (-1.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NVO News Items

NVO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVO News Highlights

  • For NVO, its 30 day story count is now at 37.
  • Over the past 26 days, the trend for NVO's stories per day has been choppy and unclear. It has oscillated between 1 and 15.
  • The most mentioned tickers in articles about NVO are MG, STEP and PEN.

Latest NVO News From Around the Web

Below are the latest news stories about Novo Nordisk A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

Novo Nordisk meets primary endpoint in mid-stage trial for patients with high cardiovascular risk

Novo Nordisk ([[NVO]] +1.7%) announced that its monoclonal antibody ziltivekimab met the primary endpoint in a Phase 2 trial that was designed to assess its potential to reduce the levels of inflammatory biomarkers linked to atherosclerosis. Atherosclerosis which is characterized by accumulation of lipids on blood vessels, is the major...

Seeking Alpha | May 17, 2021

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 17 May 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme initiated 7 May 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.3 billion in the period from 10 May 2021 to 3 August 2021. Since the announcement of the programme, the following transactions have been made: Number ofB sharesAveragepurcha...

Yahoo | May 17, 2021

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Vaccitech plc (NASDAQ: VACC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 13) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) ADC Therapeutics SA (NYSE: ADCT ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Achilles Therapeutics plc (NASDAQ: ACHL ) Akouos, Inc. (NASDAQ: AKUS ) (announced its first-quarter results) Applied Genetic Technologies Corporation (NASDAQ: AGTC ) Aprea Therapeutics, Inc. (NASDAQ: APRE ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) Atreca, ...

Benzinga | May 14, 2021

Novo Nordisk, Eli Lilly Obesity Drugs Could Be Game Changers

Medications in a new class of drug that seem to offer substantial advantages over current treatments

Yahoo | May 13, 2021

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ: HOOK ) Novo Nordisk A/S (NYSE: NVO ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 11) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) ADC Therapeutics SA (NYSE: ADCT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akouos, Inc. (NASDAQ: AKUS ) (reacted to presentation of non-clinical data on gene therapy candidates at the American Society of Gene and Cell Therapy meeting) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Ap...

Benzinga | May 12, 2021

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV ) - Its Allergan subsidiary announced a deal to buy Soliton, Inc. (NASDAQ: SOLY ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Quest Diagnostics Incorporated (NYSE: DGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 10) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Aquestive Therapeutics, Inc. (NASDAQ: A...

Benzinga | May 11, 2021

Novo Nordisk issues voluntary nationwide recall of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy® product samples due to improper storage temperature conditions

PLAINSBORO, N.J. , May 7, 2021 /PRNewswire/ -- Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir ® , Tresiba ® , Fiasp ® , Novolog ® and Xultophy ® , to the consumer level. These products are being recalled because they were stored at temperatures below storage requirements. This recall only impacts product samples and does not impact product that has been broadly distributed to pharmacies or mail-order services. If product samples are exposed to temperatures below 32°F, it could cause a lack of efficacy and damage to the cartridge and pen-injectors. If product from an improperly stored vial, cartridge or pen-injector is used, there is a risk that you might not receive the right amount of medicine as intended which may lead to hyperglycemia...

Benzinga | May 7, 2021

Trading in Novo Nordisk shares by board members, executives and associated persons on 7 May 2021

Bagsværd, Denmark, 7 May 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please see the attached PDF document for detailed information about this trading. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blo...

Yahoo | May 7, 2021

Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme

Bagsværd, Denmark, 7 May 2021 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2021 share repurchase programme of up to a total of DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. The transaction price is DKK 461.04 per share and has been calculated as the three-day volume weighted average market price from 5 May 2021 to 7 May 2021 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results. Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.5% of the share capital and 76.9% of the votes. Following the transaction, Novo Holdings A/S own...

Yahoo | May 7, 2021

PFE vs. NVO: Which Stock Should Value Investors Buy Now?

PFE vs. NVO: Which Stock Is the Better Value Option?

Yahoo | May 7, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7202 seconds.